# Plaisance Capital Management

> Plaisance Capital Management is a VC fund in Natick backing Health Care and Biotechnology. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Natick, United States
- Total investments: 13
- Last investment: May 2026
- Lead investor: 8%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/plaisancecapital
- Website: https://www.plaisancecap.com

Plaisance Capital Management is a VC fund in Natick focused on Health Care and Biotechnology. Plaisance Capital Management identifies and invests in biotechnology startups.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 23% |
| Biotechnology | 3 | 23% |
| Pharmaceutical | 3 | 23% |
| Dental | 1 | 8% |
| Robotics | 1 | 8% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 15% |
| Seed | 1 | 8% |
| Series B | 1 | 8% |
| Series C | 1 | 8% |
| Series D | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 23% |
| China | 1 | 8% |
| Canada | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $109M | Series D | May 18, 2026 |  |
| BlossomHill Therapeutics | BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $84M | Series B | Dec 10, 2025 |  |
| Full-Life Technologies | Full-Life Technologies Limited (“Full-Life”) is a fully integrated global RadioTherapeutics company headquartered in Shanghai, China with operations in Europe. | $50M | Series C | Sep 29, 2025 |  |
| Reunion Neuroscience | Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M | Series A | Sep 16, 2025 |  |
| BlossomHill Therapeutics | BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. | $100M | Series B | Jan 02, 2024 |  |
| Stellaromics | Stellaromics is a biotechnology company that specializes in 3D in situ multi-omic analysis technology. | $25M | Series A | Nov 02, 2023 |  |
| Corsair Pharma | Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients. | $23M | Series B | Sep 20, 2023 |  |
| Smartlens | Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $6.1M | Series A | Jul 11, 2023 |  |
| Sedec Therapeutics | Targeting novel protein acylation pathways for treating inflammatory and autoimmune diseases |  | Seed | Jan 01, 2023 |  |
| Proteovant Therapeutics | Proteovant Therapeutics is a biotechnology company that utilizes protein degradation research in the development of medicines for diseases. |  | Seed | Jan 01, 2023 |  |

10 of 13 investments shown.

## Co-investors
- [Junson Capital](https://shizune.co/investors/profile/junson-capital) — VC Fund, 3 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 3 deals together
- [Chengwei Capital](https://shizune.co/investors/profile/chengwei-capital) — VC Fund, 2 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Plaisance Capital Management invest in?

Plaisance Capital Management invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Plaisance Capital Management last invest?

The most recent investment recorded for Plaisance Capital Management closed in May 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co